sj-pdf-1-msj-10.1177_13524585211035333 – Supplemental material for A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment

Cohen, Jeffrey A; Cameron, Michelle H; Goldman, Myla D; Goodman, Andrew D; Miller, Aaron E; Rollins, Anne; Llorens, Lily; Patni, Rajiv; Elfont, Robert; Johnson, Reed

doi:10.25384/SAGE.16529273.v1

sj-pdf-1-msj-10.1177_13524585211035333.pdf (650.47 kB)

sj-pdf-1-msj-10.1177_13524585211035333 – Supplemental material for A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment

journal contribution

posted on 2021-08-28, 12:06 authored by Jeffrey A Cohen, Michelle H Cameron, Myla D Goldman, Andrew D Goodman, Aaron E Miller, Anne Rollins, Lily Llorens, Rajiv Patni, Robert Elfont, Reed Johnson

Supplemental material, sj-pdf-1-msj-10.1177_13524585211035333 for A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment by Jeffrey A Cohen, Michelle H Cameron, Myla D Goldman, Andrew D Goodman, Aaron E Miller, Anne Rollins, Lily Llorens, Rajiv Patni, Robert Elfont and Reed Johnson in Multiple Sclerosis Journal